Ignite Creation Date:
2024-10-26 @ 3:38 PM
Last Modification Date:
2024-10-26 @ 3:38 PM
Study NCT ID:
NCT06567314
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-08-21
Brief Title:
Phase 2 Study of Ivonescimab in Patients With Cutaneous Squamous Cell Carcinoma
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Phase 2 Study of Ivonescimab in Patients With Cutaneous Squamous Cell Carcinoma
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To learn if ivonescimab can help to control advanced cSCC The safety and effects of ivonescimab will also be studied
Detailed Description:
Primary Objective - To determine the ORR of ivonescimab in participants with cSCC
Secondary Objectives
To evaluate other indicators of the antitumor efficacy of ivonescimab in participants with cSCC
To evaluate the safety and tolerability of ivonescimab in participants with cSCC
Exploratory Objective
- To evaluate potential predictors of response and resistance to ivonescimab in participants with cSCC
Secondary Objectives
To evaluate other indicators of the antitumor efficacy of ivonescimab in participants with cSCC
To evaluate the safety and tolerability of ivonescimab in participants with cSCC
Exploratory Objective
- To evaluate potential predictors of response and resistance to ivonescimab in participants with cSCC
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None